Andy, I beleive that risk has almost gone. A2M are very careful how they promote their products. They have a lot of clinical evidence to back up their claims. If they didn't, any other company can come after them. The counter sue was a bluff by Lion before the Chinese clinical study results were published. Bluff was called and they effectively have lost.
Ann: Settlement of Australian Legal Dispute, page-28
-
- There are more pages in this discussion • 83 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.22 |
Change
-0.105(1.97%) |
Mkt cap ! $3.801B | |||
| Open | High | Low | Value | Volume |
| $5.26 | $5.29 | $5.20 | $5.634M | 1.075M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 12490 | $5.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.22 | 12925 | 14 |
View Market Depth
| Last trade - 13.16pm 07/11/2024 (20 minute delay) ? |
| A2M (ASX) Chart |